This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentEventsMaterialsVideosLet's connectLet's ConnectPfizer medical informationOnConnect
DosingDosingDosing ScheduleDose ModificationsAboutAboutStudy MethodologyEfficacy & SafetyEfficacy & Safety Progression-free Survival & Objective Response RateCNS EfficacyGuidelinesSafety TablesSafety Overview

Menu

Close

DosingDosingDosing ScheduleDose ModificationsTherapy ManagementTherapy ManagementHyperlipidaemiaOedemaILD/PneumonitisCNS EffectsSummarySupport & ServicesSupport & ServicesSummary of Prescribing InformationDownloadable ResourcesEvents & WebinarsVideosUseful Links

LORBRIQUA® (lorlatinib) is indicated for the treatment of adult patients with ALK+ metastatic NSCLC.1

Hyperlipidaemia

Therapy management guidance for hyperlipidaemia1-3

  • The median time to onset was 15 days for both hypercholesterolaemia and hypertriglyceridaemia
     
  • Hyperlipidaemia was generally managed with lipid-lowering agents and dose interruptions, and in more severe (Grade ≥3) cases, it was managed with dose modifications
     
  • 81% of patients required initiation of lipid-lowering medications
      
    • Median time to start of LLT: 20 days
       
    • Pitavastatin, pravastatin or rosuvastatin is the recommended statin based on its drug interaction potential
       
    • If high-intensity statin therapy is needed, rosuvastatin is recommended based on its low involvement with CYP450 enzymes that are able to interact with LORBRIQUA® (lorlatinib)
       
  • Monitor serum cholesterol and triglycerides before initiating LORBRIQUA®, 1 and 2 months after initiating LORBRIQUA® and periodically thereafter
     
  • The incidence of dose interruptions due to hyperlipidaemia in the LORBRIQUA® clinical trials is as follows:
      
    • 3.4% due to hypercholesterolaemia and 7% due to hypertriglyceridaemia in the CROWN trial
       
    • 3.4% due to hypercholesterolaemia and 6% due to hypertriglyceridaemia in the Phase 1/2 trial

General Dose Modification Guidelines for Lorlatinib-related Adverse Reactions by CTCAE Grade2,*

   

   

Adapted from Bauer TM, et al. 2019.

   

Tab Number 1

Tab Number 2

Tab Number 3

This is the First tab of content! Lorem ipsum ap dolor sit amet consectetur adipisicing elit. Inventore facere ulla m tempore veritatis, corporis soluta animi esse dolores molestias, quisquam nam sapient e, quo mollitia corrupti nulla! Rerum enim quis iusto.Quidem eaque odio voluptatibus repudiandae o bcaecati iure dicta repellendus quod! Autem porro ducimus officiis a debitis iure unde omnis! Nes ciunt odio pariatur, sequi laudantium quisquam quae dolor minus error totam.

This is the Second tab of content! Lorem ipsum ap dolor sit amet consectetur adipisicing elit. Inventore facere u llam tempore veritatis, corporis soluta animi esse dolores molestias, quisquam nam sapie nte, quo mollitia corrupti nulla! Rerum enim quis iusto.Quidem eaque odio voluptati bus repudiandae obcaecati iure dicta repellendus quod! Autem porro ducimus officiis a debitis iure unde omnis! Nesciunt odio pariatur, sequi laudantium quisquam quae dolor minus error totam.

This is the Third tab of content! Lorem ipsum ap dolor sit amet consectetur adipisicing elit. Inventore facere u llam tempore veritatis, corporis soluta animi esse dolores molestias, quisquam nam sapie nte, quo mollitia corrupti nulla! Rerum enim quis iusto.Quidem eaque odio voluptati bus repudiandae obcaecati iure dicta repellendus quod! Autem porro ducimus officiis a debitis iure unde omnis! Nesciunt odio pariatur, sequi laudantium quisquam quae dolor minus error totam.

Tab Number 1

Tab Number 2

Tab Number 3

This is the First tab of content! Lorem ipsum ap dolor sit amet consectetur adipisicing elit. Inventore facere ulla m tempore veritatis, corporis soluta animi esse dolores molestias, quisquam nam sapient e, quo mollitia corrupti nulla! Rerum enim quis iusto.Quidem eaque odio voluptatibus repudiandae o bcaecati iure dicta repellendus quod! Autem porro ducimus officiis a debitis iure unde omnis! Nes ciunt odio pariatur, sequi laudantium quisquam quae dolor minus error totam.

This is the Second tab of content! Lorem ipsum ap dolor sit amet consectetur adipisicing elit. Inventore facere u llam tempore veritatis, corporis soluta animi esse dolores molestias, quisquam nam sapie nte, quo mollitia corrupti nulla! Rerum enim quis iusto.Quidem eaque odio voluptati bus repudiandae obcaecati iure dicta repellendus quod! Autem porro ducimus officiis a debitis iure unde omnis! Nesciunt odio pariatur, sequi laudantium quisquam quae dolor minus error totam.

This is the Third tab of content! Lorem ipsum ap dolor sit amet consectetur adipisicing elit. Inventore facere u llam tempore veritatis, corporis soluta animi esse dolores molestias, quisquam nam sapie nte, quo mollitia corrupti nulla! Rerum enim quis iusto.Quidem eaque odio voluptati bus repudiandae obcaecati iure dicta repellendus quod! Autem porro ducimus officiis a debitis iure unde omnis! Nesciunt odio pariatur, sequi laudantium quisquam quae dolor minus error totam.

H4 (Mobile)

   

*Grade based on the NCI CTCAE version 4.03.

   

ALK+, anaplastic lymphoma kinase-positive; CTCAE, Common Terminology Criteria for Adverse Events; CYP450, cytochrome P450; LLT, lipidlowering therapy; NCI, National Cancer Institute; NSCLC, non-small cell lung cancer; ULN, upper limit of normal.

   

 References:

Lorbriqua. Local product document. Pfizer; 2021. LPD Version 7.0  LPDLOR102022Bauer TM, Felip E, Solomon BJ, et al. Clinical Management of Adverse Events Associated with Lorlatinib. Oncologist. 2019;24(8):1103-1110.Reed M, Rosales AS, Chioda MD, Parker L, Devgan G, Kettle J. Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners.
Adv Ther. 2020;37(6):3019-3030.

   

Please click the Prescribing Information link to view the safety and adverse events information of LORBRIQUA®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.​​​​​​

   

PP-LOR-IND-0129 June 2022

Therapy Management
 Badge

American Cancer Society

The American Cancer Society funds and conducts research, shares expert information and provides support for patients who have been affected by cancer.

 Learn moreLoading


Lung Cancer Foundation of America

The Lung Cancer Foundation of America aims to improve the survivorship of patients with lung cancer through the funding of transformative science.

 Learn moreLoading
Contact Center for Health Care Professionals | Monday to Saturday 9:00 AM to 6:00 PM IST(exlcuding public holidays)

0008000503188

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign OutThese pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.

Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
PP-LOR-IND-0129

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2024 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use only of Registered medical practitioners* or a Hospital or a Laboratory

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.

 

If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0597  01 Mar 2024Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0597  01 Mar 2024